共 50 条
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
被引:259
|作者:
Saper, Joel R.
[1
]
Dodick, David W.
[2
]
Silberstein, Stephen D.
[3
]
McCarville, Sally
Sun, Mark
Goadsby, Peter J.
[4
]
机构:
[1] Michigan Head Pain & Neurol Inst, Ann Arbor, MI 48104 USA
[2] Mayo Clin, Rochester, MN 55905 USA
[3] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源:
关键词:
Intractable chronic migraine headache;
chronic migraine headache;
device implantation;
headache days;
occipital nerve stimulation;
CHRONIC CLUSTER HEADACHE;
TERM-FOLLOW-UP;
DOUBLE-BLIND;
NEUROSTIMULATION;
TOPIRAMATE;
INJECTION;
EFFICACY;
SAFETY;
BURDEN;
BLOCK;
D O I:
10.1177/0333102410381142
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache >= 15 days per month. Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.
引用
收藏
页码:271 / 285
页数:15
相关论文